
mRNA cancer vaccines are on the horizon | Office for Science and Society
The comment was buried near the end of a news article about an experimental vaccine. Keep in mind: This particular vaccine was not intended for healthy people to prevent future infection. It was being tested on people with advanced skin cancer as a form of treatment. Still, some eligibles shook their heads when asked if they wanted it.
“Misinformation about the safety of mRNA COVID-19 vaccines,” the commentary said, quoting one of the doctors who led the trial, “has made it difficult for some centers in the United States to recruit participants.” This situation is made worse by the fact that the health wing of the US government, led by RFK Jr., ended funding for the development of an mRNA vaccine a year ago.
It’s a bit absurd that people now have notice about the molecules I studied in undergrad – the very molecules that give us life. DNA is bad and foods that contain it need to be labeled so you can avoid them! Peptides and proteins are the future!
And RNA? Nobody wants RNA. We simply don’t know enough. Maybe in 20, 50, 100 years, but now? Too dangerous!
Those who refuse it have rarely worked with it in the laboratory. We used to say that you look to RNA and it disintegrates. This small fragile molecule is in reality scare people with cancer?
It’s really a shame. Cancer vaccines have been a credible dream ever since William Coley infected cancer patients with bacteria to boost their immune systems in the late 1800s. With a lot of hard work, we appear to be on the cusp of a major development. Strands of RNA can be created and packaged into tiny fat droplets to wake up our immune system to attack our cancer.
However, the path to get there is strewn with pitfalls and promising failures.
The Invisibility Cloak Problem
You would think that our immune system would detect a tumor growing inside us. After all, a tumor – a mass of our own cells dividing uncontrollably – shouldn’t be there, and our immune system’s main job is to find the things that shouldn’t be there and take care of them.
But just like the Klingons and Romulans of Star Trekcancerous tumors have acquired a masking device (of sorts). They can escape immune surveillance. The very space around the tumor is altered, making it unsuitable for immune cells to grow, and the cancer cells secrete substances that deactivate bloodhounds that would reveal their location. The goal of a cancer vaccine is to make our immune cells realize that they have been tricked and launch an attack.
Researchers have been valiantly trying to develop safe and effective cancer vaccines for some time, but an accumulation of lead balloons has made the whole thing look increasingly fanciful. I had a supervisor in grad school (circa 2012) who snickered whenever the topic of cancer vaccines was brought up. It was a stupid waste of time, he said. This would never work.
Of course, we are technically had cancer vaccines. Just over one in eight cancers is caused by an infectious agent like a virus, and we have vaccines to protect against it. prevent some of them. The HPV vaccine protects against cervical cancer, while the hepatitis B vaccine stops a virus that causes a subset of liver cancer.
But developing vaccines that to treat cancer was not easy. A few have been approved, such as sipuleucel-T (brand name Provenge) for prostate cancer and nadofaragene firadenovec-vncg (Adstiladrin) for bladder cancer. Bacillus Calmette-Guérin or BCG, which is a tuberculosis vaccine, has also been shown to help improve the immune response in some cases of bladder cancer. These sporadic successes are the graves of many, many cancer vaccines that simply did not survive the obstacle course that we imposed on them. Most experimental cancer vaccines betray their initial promises: we see objectively that they awaken the immune system, of course, but no clinical improvement ensues. It is not enough that the T lymphocytes and B lymphocytes present in our blood are stimulated by a cancer vaccine; patients must survive longer overall or without recurrence, or their cancer must remain stable for the vaccine to be considered a success.
Messenger RNA appears to be the missing ingredient.
A programmable “wanted” poster
Scientifically, it is very strange that messenger RNA has been demonized by some during the pandemic. It is one of the three central elements in the evolution of life at the molecular level.
DNA encodes standing instructions on how to make specific proteins. Messenger RNA (or mRNA) is transcribed from DNA as a kind of fragile, temporary copy, which is then translated into the final protein. DNA, RNA, proteins: this is the circle of life.
mRNA COVID-19 vaccines work by introducing an RNA copy of the instructions for making the virus’s spike protein into the body. But you can create an RNA molecule that codes for just about anything, much like a VHS tape might record a music show. Citizen Kane just as well as pornography. The principle is the same. You create the required mRNA molecule, package it in a protective shell, and inject it into a person. This molecule will be swallowed by a dendritic cell, which circulates in the blood. The cell will make the protein encoded by the mRNA and display it on its surface. Other blood cells will attach to it, and this handshake is like an order: if you see this “thing”, attack it.
In the case of cancer, this “thing” is a protein either in overabundance in the tumor or made only in the tumor. Doctors take a biopsy of the patient’s tumor, which is then sent to the laboratory. The DNA of these cancer cells is sequenced letter by letter, in order to find abnormal sequences full of unique mutations. Scientists must then select the “best” ones: increasingly, artificial intelligence is used to comb through all these anomalies to find those that will likely trigger the right immune response. A few tests are performed in the laboratory and the final set of abnormal proteins is encoded into mRNA, packaged into tiny fat droplets and made into a vaccine that is injected at regular intervals into the cancer patient over the course of several weeks.
Recently, we heard encouraging news that this approach might work. Clinical trials typically occur in three phases, starting with safety testing in a small number of people before eventually progressing to effectiveness testing in larger groups. Preliminary results from the first-ever Phase III trial of an mRNA cancer vaccine were recently revealed, to much excitement.
Like the dials of a radio
Most trials of mRNA cancer vaccines are done on a dozen or fewer patients, without a control group: the goal is to see how safe they are, and so far, these vaccines have been very well tolerated. Given the small size of these studies, it was quite a change of pace to see the results of a trial involving 1,137 patients.
They all suffered from melanoma, a particularly aggressive type of skin cancer. Each patient underwent surgery to remove the tumor as best as possible, then was randomly assigned to one of two groups. They all received an injection of an antibody called pembrolizumab (Keytruda), which is the standard of care and already attempts to wake up the patient’s immune system to the presence of cancer. But patients in a group Also received a placebo injection, while patients in the other group received a personalized mRNA vaccine called intismeran autogene.
Two years later, 70% of patients in the placebo group were still alive and their cancer had not returned; in the mRNA vaccinated group, this percentage increased to just over 82%. The most common side effects of the vaccine were the ones we already see with something like the flu shot: fever, arm pain, fatigue. It is too early to know more, for example whether long-term survival is increased, but these initial results are certainly encouraging.
There are many other clinical trials of mRNA cancer vaccines, but the apparent success of one does not guarantee the triumph of all. Before being tested on humans, these vaccines are experimented on mice, and while mice are decent models for many human diseases, their immune systems are different enough that their results don’t always translate to us. Additionally, mRNA cancer vaccines often rely on sequencing the DNA of each patient’s tumor to select the targets most likely to work. (Some experimental cancer vaccines instead focus on targets that are likely to be shared by many patients with a specific cancer, but they are a minority.) This type of selection takes time, time that advanced cancer patients don’t have, and requires careful selection.
These challenges, however, could be the rules of the game. A recently published paper by a team at the MD Anderson Cancer Center in Texas posits that these real-world problems facing researchers, searching for a single solution, might actually be like radio dials that need to be adjusted to personalize each cancer vaccine. You want the vaccine to undermine the immune system, but not to the point of harming the patient. You want it to alert specific cells of the immune system, but not those that will silence the alarm. You want the body to produce antibodies without depleting the cells that produce them.
These dials can be adjusted by changing certain letters on the RNA molecule; by modifying the fat capsule in which it is located; choosing where to inject the vaccine; by modifying the vaccination schedule; choosing the right anticancer drug with which to administer it; etc. Each component of this technology must be brought into its Goldilocks zone for a particular patient, which may be different from another patient.
Indeed, these promising vaccines are like good clothes: they need to fit, and scientists are only just beginning to understand how to do that.
But regardless of their future success on the page, these cancer mRNAs…
Gn Health